Editas Medicine
EDIT
206 hedge funds and large institutions have $64.8M invested in Editas Medicine in 2024 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 61 increasing their positions, 57 reducing their positions, and 58 closing their positions.
7% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 57
2% more call options, than puts
Call options by funds: $396K | Put options by funds: $388K
5.01% less ownership
Funds ownership: 66.86% → 61.84% (-5%)
10% less funds holding
Funds holding: 229 → 206 (-23)
33% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 58
65% less capital invested
Capital invested by funds: $188M → $64.8M (-$123M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$3.7M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$2.87M |
| 3 |
MAM
Monaco Asset Management
Monaco
|
+$2.73M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.79M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$16.7M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$5M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
-$4.02M |
| 4 |
BlackRock
New York
|
-$1.83M |
| 5 |
Millennium Management
New York
|
-$1.54M |
EDIT Hedge Fund Activity: Q4 2024 in Review
206 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q4 2024, worth a combined $64.8M — down 65% from $188M a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of EDIT and 39 opened new positions — a net loss of 19 holders — while 57 trimmed existing stakes and 61 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $3.7M. The largest seller was Deep Track Capital, exiting entirely with an estimated $16.7M sold.
- 206 institutional investors held Editas Medicine (EDIT) as of Q4 2024, down from 229 in Q3 2024.
- Funds reported $64.8M of Editas Medicine stock for Q4 2024, down 65% quarter-over-quarter.
- 39 funds opened new Editas Medicine positions in Q4 2024 and 58 closed out, a net change of -19 holders.
- The largest Editas Medicine buyer in Q4 2024 was Renaissance Technologies, an estimated $3.7M added.
- The largest Editas Medicine seller in Q4 2024 was Deep Track Capital, an estimated $16.7M sold.
Based on aggregated 13F filings for Q4 2024.